Kobayashi Pharmaceutical Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Satoshi Yamane
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | 0.01% |
| Management average tenure | no data |
| Board average tenure | 6.1yrs |
Recent management updates
Recent updates
Calculating The Intrinsic Value Of Kobayashi Pharmaceutical Co., Ltd. (TSE:4967)
Nov 27
Kobayashi Pharmaceutical's (TSE:4967) Soft Earnings Are Actually Better Than They Appear
Aug 21Getting In Cheap On Kobayashi Pharmaceutical Co., Ltd. (TSE:4967) Is Unlikely
Aug 04Investor Optimism Abounds Kobayashi Pharmaceutical Co., Ltd. (TSE:4967) But Growth Is Lacking
Apr 21Estimating The Fair Value Of Kobayashi Pharmaceutical Co., Ltd. (TSE:4967)
Apr 03Investors Met With Slowing Returns on Capital At Kobayashi Pharmaceutical (TSE:4967)
Feb 27CEO
Satoshi Yamane (64 yo)
less than a year
Tenure
Mr. Satoshi Yamane is President of Kobayashi Pharmaceutical Co. Ltd. from July 2024 and serves as Senior MD & Head of Sustainability Management Headquarters since January 2024. He was General Manager of Gr...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 18.5yrs | no data | 0.011% ¥ 47.7m | |
| Independent Outside Director | 11.5yrs | no data | no data | |
| Independent Outside Director | 2.8yrs | no data | no data | |
| Outside Audit & Supervisory Board Member | 9.5yrs | no data | no data | |
| Independent Outside Director | 8.5yrs | no data | no data | |
| Independent Outside Director | 2.8yrs | no data | no data | |
| Full-time Audit & Supervisory Board Member | 3.8yrs | no data | no data | |
| Outside Audit & Supervisory Board Member | 1.8yrs | no data | no data |
6.1yrs
Average Tenure
66yo
Average Age
Experienced Board: 4967's board of directors are considered experienced (6.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 08:56 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kobayashi Pharmaceutical Co., Ltd. is covered by 21 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mitsuko Miyasako | Barclays |
| Ritsuko Tsunoda | BofA Global Research |
| Daisuke Yamaguchi | Citigroup Global Markets Japan Inc. |